Better Health for All

Lantheus's core business, including diagnostic and therapeutic products like PYLARIFY, DEFINITY, NEUROLITE, and various AI solutions, is entirely focused on finding, fighting, and following disease to improve patient outcomes.

No products are identified as having negative health consequences. The company reported R&D investments of $77.7 million in 2023, $311.7 million in 2022, and $45.0 million in 2021, primarily for clinical development candidates. For risk transparency, DEFINITY and other ultrasound enhancing agents carry an FDA-required boxed warning for potentially serious safety concerns, and labels have been amended in 2021 and 2023 due to adverse events. The company includes a 'Risk Factors' section in its annual report. Lantheus's operations involve the transport, use, handling, storage, exposure to, and disposal of hazardous and radioactive materials and wastes, and it developed a stormwater management plan in 2020. Lantheus is subject to data protection laws and regulations, and its enrollment forms for patient support can be submitted via email or fax. The company conducts clinical trials to evaluate the safety and effectiveness of investigational products, with one trial (SPLASH) having 10% Black or African American participants. Lantheus has an Expanded Access Program Policy but currently has no open programs for patient enrollment. The company offers financial assistance programs for PYLARIFY scans but faces uncertainties regarding reimbursement and controls over drug pricing. Lantheus provides basic education and resources for patients and providers, and its Medical Affairs and Medical Information functions educate physicians. The company's products are primarily for diagnosis and treatment, with limited focus on preventative health measures like scan reminders. Lantheus sponsors three Employee Resource Groups and focuses on diverse hiring, but specific health equity programs are not detailed. The company's patent for PYLARIFY expires in 2037, and it is involved in patent infringement litigation for PNT2003.

Fair Money & Economic Opportunity

Lantheus Holdings, Inc. is a commercial-stage company that develops, manufactures, and sells diagnostic and therapeutic medical imaging products to hospitals, clinics, and imaging centers.

Its core business does not involve lending, insuring, moving, or storing money for consumers. Therefore, all KPIs related to fair money and economic opportunity, which are designed for financial institutions offering consumer credit or deposit products, are not applicable to Lantheus's operations. The company does not offer consumer credit products, manage customer financial data, or have a loan/insurance book, resulting in a '0' score for all relevant KPIs.

Fair Pay & Worker Respect

For fiscal year 2024, the CEO's total compensation was $13,495,697, while the median employee pay was $203,408, resulting in a CEO to median employee pay ratio of 66:1.

As of December 31, 2023, none of the company's 834 employees were represented by a collective bargaining agreement. The company states it is focused on pay equity and regularly assesses pay among similar roles, but no specific pay equity ratio for women or minorities was provided. Employee engagement, based on Glassdoor reviews, shows 51% of employees would recommend working at Lantheus to a friend and 49% approve of the CEO. The compensation and benefits rating on Glassdoor is 4.1 out of 5, though this decreased by 9% over the last 12 months. The company's compensation package includes healthcare benefits, but no specific percentage of the workforce covered by employer-funded health insurance was disclosed.

Fair Trade & Ethical Sourcing

Lantheus states that most contracts with its direct suppliers have been in force for many years and historically did not require information regarding the origin of conflict minerals.

The company seeks to contractually require new suppliers to investigate upstream sources for conflict minerals. For conflict minerals, the source for two products could not be determined. The company aims to do business with minority-owned, female-owned, veteran-owned, and disabled veteran-owned businesses, but less than 1% of the procurement budget is directed to these diverse suppliers.

Honest & Fair Business

Lantheus Holdings, Inc. has an ESG Score of 26 from S&P Global, indicating partial disclosure with key gaps in governance reporting.

The company maintains an externally administered whistleblower hotline and website, prominently advertised to employees, where anonymity is protected if requested. The company is required to prepare an accounting restatement due to material noncompliance with financial reporting requirements under securities laws. The company's policies mandate compliance with anti-bribery laws, including the Foreign Corrupt Practices Act (FCPA) and the U.K. Bribery Act. Third-party cybersecurity audits are performed at least annually, and third-party security reviews and testing of the company's network, processes, and systems are conducted periodically.

Kind to Animals

Lantheus Holdings, Inc. conducts pre-clinical trials of its drugs on animals, with its lead molecule LMI 1174 having been used in various animal models.

The company's involvement in animal testing is noted as significant. Lantheus is listed on the Cruelty Free Investing list for exploiting animals due to this practice, indicating no products are certified cruelty-free. The company does not explicitly state an animal testing policy.

No War, No Weapons

Lantheus Holdings, Inc. aims for all products, materials, and components to be free of Conflict Minerals or sourced from outside Covered Countries, recycled sources, or validated conflict-free smelters/refiners.

The company is required to file an annual report with the U.S. SEC under Section 1502 of the Dodd-Frank Act and utilizes due diligence measures for conflict minerals designed to conform with OECD Due Diligence Guidance. For one product, necessary conflict minerals originated solely from recycled or scrap resources. However, for two other products, the company was unable to determine the source of the necessary conflict minerals for the reporting period of January 1 to December 31, 2024. Suppliers are expected to communicate the company's principles to their supply chain and periodically evaluate their supply chain’s compliance with applicable laws and principles. The company reserves the right to terminate relationships with non-compliant suppliers and expects them to develop and implement remediation plans. The company's Supplier Code of Conduct includes a strict zero-tolerance policy regarding bribery and corruption.

Planet-Friendly Business

Lantheus has developed a stormwater management operations and maintenance plan at its North Billerica campus to minimize pollution to adjacent wetlands.

This plan includes regular inspections and cleaning of catch basins and piping, increased street and parking lot cleaning, and an updated snow removal plan to reduce impact. The company implemented third-party environmental software in 2024 to strengthen regulatory compliance and data collection. No environmental compliance violations were reported in the provided articles.

Respect for Cultures & Communities

Lantheus Holdings, Inc. has established 5 formal partnerships with organizations including the Alzheimer’s Association MA/NH Chapter, American Heart Association, ZERO Prostate Cancer, Michigan Men’s Health Foundation, and PHEN.

The company supports various charitable initiatives, such as raising over $200,000 for the Alzheimer’s Association MA/NH Chapter and $67,000 for the American Heart Association Boston Heart Walk in 2025. In 2024, it raised over $200,000 for the Prostate Cancer Foundation through its annual golf tournament. The company also supports the United Way of Massachusetts Bay of Merrimack Valley and the Prostate Cancer Foundation’s Young Investigator Awards program. Lantheus has adopted a Supplier Code of Conduct that requires suppliers to operate ethically and responsibly, and it plans to explore more commercial arrangements with minority-owned, female-owned, and other diverse businesses.

Safe & Smart Tech

As of February 26, 2025, the company had not experienced any known cybersecurity incidents that materially affected its business strategy, results of operations, or financial condition.

The company provides ongoing, comprehensive cybersecurity awareness training to employees on phishing, malware, and other risks, and conducts company-wide training on data security matters, but no data on completion rates or effectiveness is provided. The company's systems and services undergo regular reviews by management to determine if any insufficiencies in cybersecurity exist, and third-party security reviews and testing of networks, processes, and systems are conducted periodically. The company states it complies with all applicable laws, rules, and regulations, including GDPR, CCPA, and FDA reporting requirements. The company uses AI platforms, aBSI and PYLARIFY AI, in medical imaging and biomarker development, with aBSI using an artificial neural network to classify bone scan tracer uptakes. Users can update or correct their information and opt-out of mailings. The company requires suppliers to limit access to confidential information and personal data to those with a direct need to know, and to return or certify destruction of data when no longer necessary.

Zero Waste & Sustainable Products

Lantheus has implemented six waste reduction initiatives. In 2020, the company developed a stormwater management operations and maintenance plan, which included regular inspection and cleaning of catch basins, increased street and parking lot cleaning, an updated snow removal plan, and the use of salt brine as a pretreatment for winter storms.

Additionally, Lantheus participates in the RightCycle Program for recycling nonhazardous laboratory gloves, single-use apparel, face masks, and safety eyewear, and has co-hosted electronic recycling events. For hazardous waste, the company stores low-level radioactive waste at its facilities until materials are below regulatory limits, as allowed by licenses and permits, and contracts with third parties for waste disposal. Lantheus maintains environmental permits and nuclear licenses for its North Billerica, Massachusetts, and Somerset, New Jersey facilities, indicating compliance with relevant regulations.